KLOR-CON POWDER Rx
Generic Name and Formulations:
Potassium (as chloride) 20mEq/packet; pwd for oral soln; orange flavor.
Upsher-Smith Laboratories, Inc.
Indications for KLOR-CON POWDER:
Hypokalemia, including that caused by diuretics. Digitalis intoxication without AV block.
Take with meals and fluids. Swallow tabs whole; may break Klor-Con M tabs in half, or mix in 4oz water. Effervescent tabs, pwd: dissolve in beverage. Prophylaxis: 20mEq daily. Treatment: 40–100mEq daily in divided doses; max 20mEq/dose.
Hyperkalemia. Chronic renal disease. Acute dehydration. Heat cramps. Severe tissue destruction. Adrenal insufficiency. Familial periodic paralysis. Acidosis (potassium chloride products). Alkalosis (potassium bicarbonate products). Tablets: Esophageal compression due to enlarged left atrium. Decreased GI motility.
Discontinue if GI bleed, ulceration, or other disturbances occur. Renal or cardiac disease. Monitor potassium level, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with ACE inhibitors, spironolactone, triamterene, amiloride, and potassium-containing salt substitutes. Anticholinergics, other agents that decrease GI motility increase risk of serious GI reactions with tablets.
Hyperkalemia, GI discomfort and irritation, diarrhea, rash (rare). Tablets: Esophageal and GI ulceration, bleeding, obstruction, perforation.
M10—90, 100, 1000; M15—100, 1000; M20—90, 100, 500, 1000; Klor-Con 8, 10—100, 500; Pwd—30, 100; Klor-Con/EF—30, 100
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies